Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes

Abstract

. (2016). Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes. British Journal of Ophthalmology, 100(9), 1221 -1226 . DOI: 10.1136 /bjophthalmol-2015 Peer reviewed version Link to published version (if available): 10.1136/bjophthalmol-2015-307806 Link to publication record in Explore Bristol Research PDF-document This is the author accepted manuscript (AAM). The final published version (version of record) is available online via BMJ at http://bjo.bmj.com/content/100/9/1221. Please refer to any applicable terms of use of the publisher. University of Bristol -Explore Bristol Research General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. There was a statistically significant difference in the BCVA at month 4 (p=0.001) and at month 12 (p=0.001) compared with baseline. The mean gain in BCVA at month 4 compared with baseline was 20±15.36 letters (mean ± SD), and at month 12 was 21±16.97 letters. There was a statistically significant difference in the mean central subfield thickness (CST) at baseline versus month 4 (p=0.003) and month 12 (p=0.001). Conclusions:Patients gained vision (mean of 21 letters at 12 months) and showed reduced CST. These results support the continued use of Ranibizumab in the treatment of iCNV.

Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines and the Effect of Intravitreal Ranibizumab Treatment

“…Previous studies have reported promising results with anti-VEGF therapy in ICNV patients891042. Zhang et al .…”

Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis

“…Despite some promising results with anti-VEGF agents in treating inflammatory CNV, the current data is limited by lack of comparative studies, and further data from prospective controlled studies are required to fully determine the role of anti-VEGF therapy for the inflammatory CNV. [13] Although, intravitreal anti-VEGF has been widely used for inflammatory CNVMs, there are only a few anecdotal reports in the context of CNVM secondary to infectious and particularly fungal chorioretinitis. Successful outcomes have been documented in CNVM related to ocular toxocariasis following three consecutive injections of ranibizumab.…”

The Application of OCTA in Assessment of Anti-VEGF Therapy for Idiopathic Choroidal Neovascularization

“…In this study, about 11% of the eyes (2/17) had “medusa-shaped” lesions, and the rate of this structure was lower than those in AMD patients [ 20 ]. Previous trials proved that ICNV was treated more effectively by anti-VEGF drugs than AMD, because the former needed fewer injections and gained better vision [ 6 , 21 ]. Although the size of the lesion and duration of disease were related to treatment effects, we speculate that different neovascular morphology, such as “tree-in-bud” in ICNV and other structures in AMD, will cause different outcomes and prognosis after anti-VEGF therapy.…”

“…Because vascular endothelial growth factor (VEGF) is part of the pathophysiology of CNV [ 3 ], anti-VEGF therapy has become the first-line treatment for ICNV patients [ 4 ]. Intravitreal injection of bevacizumab and ranibizumab improves and stabilizes the vision of patient with ICNV [ 1 , 5 , 6 ].…”

“…Usually, fundus fluorescein angiography (FFA) and OCT are used to evaluate ICNV before and after treatment [ 6 ]. No systematic study has been performed on the assessment of ICNV by OCTA.…”